unknown
Stage
1
Investors
About
Biolojic Design computationally designs and programs novel therapeutic antibodies using 3D modeling and machine learning to characterize and engineer antibody binding sites. The company focuses on autoimmune disease and immuno-oncology targets to improve efficacy, specificity, and developability of human antibodies.
Explore Biolojic Design's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.